Stock Track | DIAGENS-B Soars 5.41% Intraday on Strong Q1 Earnings and AI Product Regulatory Progress

Stock Track04-22

DIAGENS-B's stock price surged 5.41% during intraday trading on Wednesday, extending its recent positive momentum in the market.

The significant upward movement appears driven by a combination of strong financial performance and promising regulatory developments. The company recently reported outstanding first-quarter results, with net profit reaching 5.8 billion yuan, representing a 12.3% year-over-year increase. Additionally, gross margin improved to 38.7%, up 2.1 percentage points quarter-over-quarter, significantly exceeding market expectations.

Beyond the financial strength, the company's AI AutoVision product has been recognized by China's National Medical Products Administration as a Class III innovative medical device. Following communication with regulatory authorities in December, no objections to the product's registration approval have been raised, with only procedural and administrative matters remaining. If ultimately approved, AI AutoVision would become the first intelligent chromosome karyotype-assisted diagnostic software to receive market authorization in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139693430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139693430","market":"hk","top_or_hot":-1,"title":"Stock Track | DIAGENS-B Soars 5.41% Intraday on Strong Q1 Earnings and AI Product Regulatory Progress","media":"Stock Track","content":"<p>DIAGENS-B's stock price surged 5.41% during intraday trading on Wednesday, extending its recent positive momentum in the market.</p><p>The significant upward movement appears driven by a combination of strong financial performance and promising regulatory developments. The company recently reported outstanding first-quarter results, with net profit reaching 5.8 billion yuan, representing a 12.3% year-over-year increase. Additionally, gross margin improved to 38.7%, up 2.1 percentage points quarter-over-quarter, significantly exceeding market expectations.</p><p>Beyond the financial strength, the company's AI AutoVision product has been recognized by China's National Medical Products Administration as a Class III innovative medical device. Following communication with regulatory authorities in December, no objections to the product's registration approval have been raised, with only procedural and administrative matters remaining. If ultimately approved, AI AutoVision would become the first intelligent chromosome karyotype-assisted diagnostic software to receive market authorization in China.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DIAGENS-B Soars 5.41% Intraday on Strong Q1 Earnings and AI Product Regulatory Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DIAGENS-B Soars 5.41% Intraday on Strong Q1 Earnings and AI Product Regulatory Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-22 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DIAGENS-B's stock price surged 5.41% during intraday trading on Wednesday, extending its recent positive momentum in the market.</p><p>The significant upward movement appears driven by a combination of strong financial performance and promising regulatory developments. The company recently reported outstanding first-quarter results, with net profit reaching 5.8 billion yuan, representing a 12.3% year-over-year increase. Additionally, gross margin improved to 38.7%, up 2.1 percentage points quarter-over-quarter, significantly exceeding market expectations.</p><p>Beyond the financial strength, the company's AI AutoVision product has been recognized by China's National Medical Products Administration as a Class III innovative medical device. Following communication with regulatory authorities in December, no objections to the product's registration approval have been raised, with only procedural and administrative matters remaining. If ultimately approved, AI AutoVision would become the first intelligent chromosome karyotype-assisted diagnostic software to receive market authorization in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02526","symbol_name":"德适-B","start_time":0,"source_url":"","article_id":"1139693430","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139693430","pubTimestamp":1776823280,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DIAGENS-B's stock price surged 5.41% during intraday trading on Wednesday, extending its recent positive momentum in the market.The significant upward movement appears driven by a combination of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02526":"德适-B"},"translate_title":"个股追踪|DIAGENS-B盘中大涨5.41%，因Q1盈利强劲和AI产品监管进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02526":1},"content_text":"DIAGENS-B's stock price surged 5.41% during intraday trading on Wednesday, extending its recent positive momentum in the market.The significant upward movement appears driven by a combination of strong financial performance and promising regulatory developments. The company recently reported outstanding first-quarter results, with net profit reaching 5.8 billion yuan, representing a 12.3% year-over-year increase. Additionally, gross margin improved to 38.7%, up 2.1 percentage points quarter-over-quarter, significantly exceeding market expectations.Beyond the financial strength, the company's AI AutoVision product has been recognized by China's National Medical Products Administration as a Class III innovative medical device. Following communication with regulatory authorities in December, no objections to the product's registration approval have been raised, with only procedural and administrative matters remaining. If ultimately approved, AI AutoVision would become the first intelligent chromosome karyotype-assisted diagnostic software to receive market authorization in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139693430","isCrawlerRequest":true}